ARIA (Atacand Renoprotection In NephropAthy Pt.) - PCR
Study identifier:D2452L00015
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients with Non-diabetic Nephropathy
Medical condition
Non-diabetic Nephropathy with hypertension
Phase
Phase 4
Healthy volunteers
No
Study drug
Candesartan Cilexetil, Candesartan Cilexetil 32mg
Sex
All
Actual Enrollment
128
Study type
Interventional
Age
18 Years - 70 Years
Date
Study Start Date: 01 Dec 2007
Primary Completion Date: 01 Aug 2009
Study Completion Date: 01 Aug 2009
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Aug 2011 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Candesartan Cilexetil | Drug: Candesartan Cilexetil 8 mg oral once daily dose Other Name: Atacand |
| Experimental: 2 Candesartan Cilexetil | Drug: Candesartan Cilexetil 16 mg oral once daily dose Other Name: Atacand |
| Experimental: 3 Candesartan Cilexetil | Drug: Candesartan Cilexetil 32mg 32 mg oral once daily dose Other Name: Atacand |
Contacts
Investigators
Principal Investigator
Da Suk Han
Severance Hospital
